Solid Biosciences Inc. (SLDB) News
Filter SLDB News Items
SLDB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SLDB News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest SLDB News From Around the Web
Below are the latest news stories about SOLID BIOSCIENCES INC that investors may wish to consider to help them evaluate SLDB as an investment opportunity.
Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceCHARLESTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 3:45 p.m. PT (6:45 p.m. ET). A live webcast of the presentation will be available on the Events page of the Investors section |
SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreich's AtaxiaSolid Biosciences rises as the FDA clears SGT-212, a gene therapy candidate, for clinical studies for the treatment of Friedreich's ataxia. |
Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia- SGT-212 is the only full-length frataxin replacement gene therapy candidate targeting the CNS and cardiac manifestations of Friedreich’s ataxia -- Dual route of administration enables direct delivery of AAV-based gene therapy to the cerebellum and heart to potentially address the most significant symptoms of the disease -- Phase 1b clinical trial initiation expected in 2H 2025 -- Company to hold a conference call tomorrow, January 8, 2025, at 8:30 AM ET -CHARLESTOWN, Mass., Jan. 07, 2025 (GLOB |
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CHARLESTOWN, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,847 restricted stock units (“RSUs”) to one newly hired employee. The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the employee’s |
Solid Biosciences Added to the Nasdaq Biotechnology IndexCHARLESTOWN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it was added to the Nasdaq Biotechnology Index® (Nasdaq: NBI) effective prior to the market open on Monday, December 23, 2024. The Nasdaq Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Na |
Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: AnalystWedbush initiated coverage on Solid Biosciences, Inc. (NASDAQ:SLDB), a gene therapy company focused on treating Duchenne muscular dystrophy (DMD). DMD is a genetic disease that causes progressive muscle weakness and wasting. SGT-003 is the leading program in Solid Biosciences' pipeline, with plans to advance additional projects toward clinical trials in 2025. The therapy uses the AAV-SLB101 capsid and a specialized cargo (nNOS binding domain) to potentially boost dystrophin expression compared t |
Solid Biosciences reports inducement grant under Nasdaq listing ruleSolid Biosciences (SLDB) announced a grant of 11,847 restricted stock units to one newly hired employee. The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the employee’s continued service with the Company through each applicable vesting date. This grant was made pursuant to the Company’s 2024 Inducement Stock Incentive Plan and was made as an inducement material to the |
Solid Biosciences Announces Collaboration with Mayo Clinic to Accelerate Gene Therapy Innovation and Advance Development of Cardiac Gene Therapies- Solid Biosciences to collaborate with Mayo Clinic’s genetic cardiology disease laboratory - - Solid to receive exclusive worldwide licenses to AAV-based Suppression-Replacement gene therapy platform and multiple next-generation cardiac gene therapy programs developed by Mayo Clinic’s Windland Smith Rice Sudden Death Genomics Lab - CHARLESTOWN, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision |
Solid Biosciences to Participate at Upcoming Investor ConferencesCHARLESTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: Citi’s 2024 Global Healthcare Conference – Miami, FLBo Cumbo, President and CEO, will participate in a panel discussion titled “Neuromuscular Disorders” on Wednesday, December 4, 2024, at 1:00 p.m. ET. Piper |
Solid Biosciences to Present at the Jefferies London Healthcare ConferenceCHARLESTOWN, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Combo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 1:30 p.m. GMT (8:30 a.m. ET). A live webcast of the presentation will be available |